drugset / Trial / NCT04650633
SHR-1701 in Patients With Recurrent/Metastatic Scchn
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single-arm, multi-center, phase II study of SHR-1701 in patients with recurrent/metastatic SCCHN
Timeline
- Start
- 2021-05-07
- Primary completion
- 2023-01
- Completion
- 2023-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | Intravenous |